Patents by Inventor Zhinan Xia
Zhinan Xia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230365705Abstract: The present application provides anti-CD93 constructs that bind to CD93 (e.g., anti-CD93 antibodies), nucleic acid molecules encoding an amino acid sequence of the anti-CD93, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of preparing the anti-CD93 construct, pharmaceutical compositions containing the anti-CD93 construct, and methods of using the anti-CD93 construct or compositions.Type: ApplicationFiled: September 28, 2021Publication date: November 16, 2023Inventors: Zirong CHEN, Roxann GUERRETTE, Gregory JONES, Shigeru KOMABA, Jian LI, Angela NORTON, Lihua WU, Zhinan XIA
-
Publication number: 20230322935Abstract: The present application provides anti-CD93 constructs that bind to CD93 (e.g., anti-CD93 antibodies), nucleic acid molecules encoding an amino acid sequence of the anti-CD93, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of preparing the anti-CD93 construct, pharmaceutical compositions containing the anti-CD93 construct, and methods of using the anti-CD93 construct or compositions.Type: ApplicationFiled: July 29, 2021Publication date: October 12, 2023Inventors: Zirong CHEN, Roxann GUERRETTE, Gregory JONES, Shigeru KOMABA, Jian LI, Angela NORTON, Lihua WU, Zhinan XIA
-
Publication number: 20230235075Abstract: The present application provides anti-CD93 constructs that bind to CD93 (e.g., anti-CD93 antibodies), nucleic acid molecules encoding an amino acid sequence of the anti-CD93, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of preparing the anti-CD93 construct, pharmaceutical compositions containing the anti-CD93 construct, and methods of using the anti-CD93 construct or compositions.Type: ApplicationFiled: June 2, 2021Publication date: July 27, 2023Inventors: Zirong CHEN, Roxann GUERRETTE, Gregory JONES, Shigeru KOMABA, Jian LI, Angela NORTON, Lihua WU, Zhinan XIA
-
Publication number: 20230129977Abstract: The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.Type: ApplicationFiled: August 11, 2022Publication date: April 27, 2023Inventors: Anthony Quinn, Alex J. Harvey, Zhinan Xia
-
Publication number: 20210301268Abstract: The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and Pharmaceutical compositions comprising the fusion polypeptide.Type: ApplicationFiled: November 25, 2020Publication date: September 30, 2021Inventors: Anthony Quinn, Alex J. Harvey, Zhinan Xia
-
Publication number: 20200354429Abstract: The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.Type: ApplicationFiled: July 30, 2020Publication date: November 12, 2020Applicant: MODERNATX, INC.Inventors: Barry Ticho, Nadege Briancon-Eris, Zhinan Xia, Athanasios Dousis, Seymour de Picciotto, Vladimir Presnyak, Stephen Hoge, Iain Mcfadyen, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
-
Patent number: 10730924Abstract: The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.Type: GrantFiled: July 2, 2018Date of Patent: August 4, 2020Assignee: ModernaTX, Inc.Inventors: Barry Ticho, Nadege Briancon-Eris, Zhinan Xia, Athanasios Dousis, Seymour de Picciotto, Vladimir Presnyak, Stephen Hoge, Iain Mcfadyen, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
-
Patent number: 10557161Abstract: The present invention is directed to isolated recombinant human ADA2 proteins, ADA2 biologically active fragments, and ADA2 fusion proteins. The proteins of the invention can be surprisingly used to restore ADA2 activity in subjects having loss-of-function mutations in ADA2 and increase differentiation of monocytes into macrophages, e.g., M2 macrophages, e.g., M2c macrophages, stimulate CD4+ T cell proliferation, and increase endothelial cell development. More specifically, the ADA2 proteins, ADA2 biologically active fragments, and ADA2 fusion proteins of the invention can be used to treat subjects having ADA2-associated diseases or disorders, including but not limited to, polyarteritis nodosa, Sneddon Syndrome, vasculitis, ischemic stroke, hemorrhagic stroke, lacunar stroke, aneurysm in the celiac artery, skin rash, skin necrosis, livedo racemosa, hepatosplenomegaly, organ failure, retinal artery occlusion, optic nerve atrophy, diplopia, cranial nerve palsy, strabismus, and low serum IgM.Type: GrantFiled: November 17, 2015Date of Patent: February 11, 2020Assignee: Alexion Pharmaceuticals, Inc.Inventors: Anthony Quinn, Zhinan Xia, Markley C. Leavitt, Mohammed Qatanani, Changlin Li, Gary Kachun Yiu
-
Publication number: 20180371047Abstract: The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.Type: ApplicationFiled: July 2, 2018Publication date: December 27, 2018Applicant: ModernaTX, Inc.Inventors: Barry Ticho, Nadege Briancon-Eris, Zhinan Xia, Athanasios Dousis, Seymour de Picciotto, Vladimir Presnyak, Stephen Hoge, Iain Mcfadyen, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
-
Publication number: 20180201969Abstract: The present invention is directed to isolated recombinant human ADA2 proteins, ADA2 biologically active fragments, and ADA2 fusion proteins. The proteins of the invention can be surprisingly used to restore ADA2 activity in subjects having loss-of-function mutations in ADA2 and increase differentiation of monocytes into macrophages, e.g., M2 macrophages, e.g., M2c macrophages, stimulate CD4+ T cell proliferation, and increase endothelial cell development. More specifically, the ADA2 proteins, ADA2 biologically active fragments, and ADA2 fusion proteins of the invention can be used to treat subjects having ADA2-associated diseases or disorders, including but not limited to, polyarteritis nodosa, Sneddon Syndrome, vasculitis, ischemic stroke, hemorrhagic stroke, lacunar stroke, aneurysm in the celiac artery, skin rash, skin necrosis, livedo racemosa, hepatosplenomegaly, organ failure, retinal artery occlusion, optic nerve atrophy, diplopia, cranial nerve palsy, strabismus, and low serum IgM.Type: ApplicationFiled: November 17, 2015Publication date: July 19, 2018Inventors: Anthony Quinn, Zhinan Xia, Markley C. Leavitt, Mohammed Qatanani, Changlin Li, Gary Kachun Yiu
-
Publication number: 20170266264Abstract: Recombinant human lysosomal acid lipase (rhLAL) containing an N-terminal truncation, a composition of truncated recombinant human LAL (TLAL), an isolated mixture comprising TLAL and at least one other form of rhLAL are disclosed. A method of purifying TLAL from a mixture of LAL proteins, pharmaceutical compositions comprising TLAL and methods of producing TLAL are further disclosed.Type: ApplicationFiled: December 21, 2016Publication date: September 21, 2017Inventors: Erin Renae Treece, Nelson Hsia, Zhinan Xia, Anthony Quinn
-
Publication number: 20170216412Abstract: The present invention provides compositions comprising an isolated mixture of recombinant human NaGlu proteins in which a substantial amount of the NaGlu proteins in the mixture has increased levels of phosphorylated mannose that confer the proteins to be efficiently internalized into human cells. The present invention also provides methods of producing such mixture of NaGlu proteins, vectors used in transgenesis and expression, host cells harboring such vectors, and methods of isolating and purifying the mixture of NaGlu proteins. The invention further provides methods of treating NaGlu associated diseases.Type: ApplicationFiled: February 10, 2017Publication date: August 3, 2017Inventors: ANTHONY QUINN, Markley C. Leavitt, Zhinan Xia
-
Publication number: 20170145393Abstract: The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.Type: ApplicationFiled: January 27, 2017Publication date: May 25, 2017Inventors: Anthony QUINN, Alex J. HARVEY, Zhinan XIA
-
Patent number: 9579366Abstract: The present invention provides compositions comprising an isolated mixture of recombinant human NaGlu proteins in which a substantial amount of the NaGlu proteins in the mixture has increased levels of phosphorylated mannose that confer the proteins to be efficiently internalized into human cells. The present invention also provides methods of producing such mixture of NaGlu proteins, vectors used in transgenesis and expression, host cells harboring such vectors, and methods of isolating and purifying the mixture of NaGlu proteins. The invention further provides methods of treating NaGlu associated diseases.Type: GrantFiled: October 11, 2012Date of Patent: February 28, 2017Assignee: ALEXION PHARMACEUTICALS, INC.Inventors: Anthony Quinn, Markley C. Leavitt, Zhinan Xia
-
Patent number: 9540621Abstract: The present invention provides a novel fusion polypeptide containing a catalytic portion of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.Type: GrantFiled: August 1, 2014Date of Patent: January 10, 2017Assignee: ALEXION PHARMACEUTICALS, INC.Inventors: Anthony Quinn, Alex J. Harvey, Zhinan Xia
-
Publication number: 20150098933Abstract: Recombinant human lysosomal acid lipase (rhLAL) containing an N-terminal truncation, a composition of truncated recombinant human LAL (TLAL), an isolated mixture comprising TLAL and at least one other form of rhLAL are disclosed. A method of purifying TLAL from a mixture of LAL proteins, pharmaceutical compositions comprising TLAL and methods of producing TLAL are further disclosed.Type: ApplicationFiled: March 1, 2013Publication date: April 9, 2015Applicant: SYNAGEVA BIOPHARMA CORP.Inventors: Erin Renae Treece, Nelson Hsia, Zhinan Xia, Anthony Quinn
-
Publication number: 20150024460Abstract: The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.Type: ApplicationFiled: October 6, 2014Publication date: January 22, 2015Inventors: Anthony Quinn, Alex J Harvey, Zhinan Xia
-
Publication number: 20140377859Abstract: The present invention provides a novel fusion polypeptide containing a catalytic portion of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.Type: ApplicationFiled: August 1, 2014Publication date: December 25, 2014Inventors: Anthony Quinn, Alex J. Harvey, Zhinan Xia
-
Patent number: 8846603Abstract: The present invention provides a novel fusion polypeptide containing a catalytic portion of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.Type: GrantFiled: March 11, 2011Date of Patent: September 30, 2014Assignee: Synageva Biopharma Corp.Inventors: Anthony Quinn, Alex J. Harvey, Zhinan Xia
-
Publication number: 20140255383Abstract: The present invention provides compositions comprising an isolated mixture of recombinant human NaGlu proteins in which a substantial amount of the NaGlu proteins in the mixture has increased levels of phosphorylated mannose that confer the proteins to be efficiently internalized into human cells. The present invention also provides methods of producing such mixture of NaGlu proteins, vectors used in transgenesis and expression, host cells harboring such vectors, and methods of isolating and purifying the mixture of NaGlu proteins. The invention further provides methods of treating NaGlu associated diseases.Type: ApplicationFiled: October 11, 2012Publication date: September 11, 2014Inventors: Anthony Quinn, Markley C. Leavitt, Zhinan Xia, Joseph Victor Rutkowski